Find cutting edge cancer clinical trials near you using the new Victorian Cancer Trials Link.

Search now


Grants-in-Aid funds high quality research into the causes, prevention, diagnosis and treatment of cancer. We are committed to funding research projects tackling all cancer types to achieve our vision for a cancer-free future.

Applications will be assessed in a two-phase process consisting of an Expression of Interest and if shortlisted, applicants will be invited to submit a Full Application.

2024 Key Dates

EOI Open: May-June
Full Applications open (via invitation only): September-October 
Outcomes advised: November

Grant selection process 

We consider eligible Grants-in-Aid applications through a two-stage competitive process (Expression of Interest and Full Application). Cancer Council Victoria's Standing Research Committee will assess each application against the selection criteria.

Important documents

By applying for this grant: 

  • you and your Administering Organisation acknowledge that you have read Cancer Council Victoria’s standard funding agreement (which can be found below); and
  • you and your Administering Organisation agree to these terms for the purpose of applying for, and if successful receiving, your grant from Cancer Council Victoria.

2023 Funding Agreement

Further information

If you have any questions about this funding, please contact:   

Research Governance Unit

Frequently asked questions and answers 

Does the budget from the EOI need to match the final budget in the Full Application? 
No, amendments to the budget can occur between stages. 

Do all CIs need to sign the application form? Or is it acceptable to provide an email with text indicating the CI has agreed to be apart of the project. 
It is preferred that all CIs sign the application form. However , should this prove to be difficult we will also accept email correspondence.

Can an applicant submit more than one application as a CIA?
No. An applicant is only able to be listed as a CIA on one application. 

Can an applicant be listed as a CI (B-J) on more than one application? 
No. A CI is only able to be listed as CI (B-J) on one application.

Additional Information and queries 
In accordance with the Guidelines “Salary requests for CIAs will be permitted provided the CIA’s PhD (or MBBS) was awarded < 13 years ago at the closing date for applications.
This date refers to the closing date of full applications.

Is an applicant who is listed as a CI (B-J) on an existing grant ending after 31 December 2022 still eligible to apply?
Yes. An  applicant who is listed as a CI (B-J) on an existing grant ending after 31 December 2022 is still eligible to apply

If an applicant is yet to be awarded their PhD does this mean they are ineligible to apply for this year's round? 
Yes, applicants must be awarded their PhD or MBBS to apply for Grants-in-Aid 

Are references able to be included within the Research Plan? 
Yes, in-test citations (e.g., Heggerty, 2021) are able to be included within the Research Plan. The reference list is excluded. 

Which title should be included within the online EOI application form?
Please use the full title/ project title for the online form. 

Does the EOI application need any breakdown of the specific costs? Or can an applicant just include a total for each of the three categories (Salary support, Direct research costs, Equipment)?
Budget does not require item breakdown at EOI stage.

The EOI form allows a maximum of 2 pages for the Research Proposal.
Does this include all of section 2 (i.e. 2.1 Background/Context, 2.2 Aims/Objectives/Hypotheses, 2.3 Methods/Design, 2.4 Experimental Plan, 2.5 Key activities and major milestones, 2.6 Budget (excluding GST), and 2.7 Is the funding requested to be spent outside of Victoria?) or is it just including the sections listed in Appendix B of the guidelines (i.e. sections 2.1 – 2.5, with sections 2.6 – 2.7 not included in the 2-page limit)?

The 2-page limit for Research Proposal is inclusive 2.1-2.7

Grants-in-Aid recipients

Projects commencing in 2023

Professor Helen Abud, Dr Rebekah Engel, Professor Paul McMurrick, A/Prof Ralf Schittenhelm, Dr Caroline Lum, Dr Stuart Archer
Monash University 
Uncovering novel mechanisms of treatment resistance in lethal bowel cancers (2023 - 2025)

A/Prof Arun Azad, Dr. Heidi Fettke, Prof. Michael Hofman, Dr. Tu Nguyen-Dumont
University of Melbourne 
Analysing “liquid biopsies” to improve prostate cancer treatment (2023 - 2025)

Prof Phillip Darcy, A/Prof Paul Beavis
University of Melbourne 
Enhancing function and persistence of CAR T cells for cancer therapy (2023 - 2025)

Dr. Nicholas Gherardin, Prof. Jamie Rossjohn
University of Melbourne
Understanding T cell receptor biology to inform next gen cell therapies (2023 - 2025)

Prof Martha Hickey, Dr Antonia Jones, Dr David Wrede, Dr Frances Petry
University of Melbourne
Salpingectomy with delayed oophorectomy to prevent ovarian cancer (TUBA WISP II) (2023 - 2025)

Prof Axel Kallies, A/Prof Shahneen Sandhu
University of Melbourne 
Improving cancer immunotherapy (2023 - 2025)

Dr Mitchell Lawrence, Prof Mark Frydenberg, Dr Susanne Ramm, Prof Anthony Joshua
Monash University
Using hormones to treat aggressive prostate cancer (2023 - 2025)

A/Prof Evelien Spelten,Prof Carlene Wilson, Dr Nienke Zomerdijk, Dr Eva Yuen, Dr Saskia Duijts
LaTrobe University 
Supporting People with a Rare Cancer living in rural and remote communities (2023 - 2025)

A/Prof Renea Taylor, Prof Matthew Watt, A/Prof David Pook
Monash University
Targeting metabolism for prostate cancer therapy (2023 - 2025)

A/Prof Alison Trainer, Prof Sue Evans, Dr Maria Bechelli, A/Prof Stephanie Best, Dr Michael Bogwitz, Dr Ainsley Campbell,
Dr Rachel DelaHunty, Dr Marion Harris, A/Prof Yoland Antill
University of Melbourne 
Extending the Cancer Registry role into the familial cancer testing process (2023 - 2024)

Dr Paul Yeh, Prof Jake Shortt, Dr Dineika Chandrananda
Monash University
ctDNA to monitor non-genomic evolution in Peripheral T-cell lymphoma (2023 - 2025)

Projects commencing in 2022

A/Prof Jeffrey Babon, Prof Warren Alexander, Dr Nadia kershaw, Dr Jason Brouwer 
Walter and Eliza Hall Institute of Medical Research
A new therapy for the treatment of Myeloproliferative Diseases (2022 -2024)

Prof Sarah-Jane Dawson, A/Prof Jessic Howell, Prof Alexander Thompson 
University of Melbourne 
Early Detection and Monitoring of Hepatocellular Carcinoma using Liquid Biopsies (2022 - 2024)

Prof Mark Dawson, Dr. Clare Gould, A/Prof Michael Dickinson, Dr Mary Ann Anderson, Prof Constantine Tam 
University of Melbourne
Novel strategies to predict and monitor response to CAR T-cell therapy in DLBCL (2022 - 2024)

Dr. Omer Gilan  
Monash University
Developing new combination therapies in acute leukaemia (2022 - 2024) 

A/Prof Paul Gregorevic, A/Prof Sean McGee    
University of Melbourne 
Giving people the strength to fight cancer: Targeting muscle to enhance survival (2022 - 2024)

Dr Nicholas Hardcastle, Dr James Korte, A/Prof Sarah Everitt, A/Prof Tomas Kron, Dr Nikki Plumridge, Dr Susan Harden, Dr Kate Moodie, Prem Krishnan, Dr Elizabeth Pearson
University of Melbourne
Sitting up for Radiotherapy (2022 - 2024)

Dr Susan Harden, Prof Penelope Schofield, Prof John Zalcberg, A/Prof Rob Stirling, Mr Ewan MacFarlane
Monash University 
Determining patterns of care and access to novel therapies for mesothelioma (2022 - 2024)

Prof Nicholas Huntington, Momeneh Foroutan, Dr Sebastian Scheer 
Monash University
Enhancing Immunotherapy Response Rates (2022 - 2024) 

A/Prof Thomas John, Prof Sean Grimmond, Dr Muhammad Alamgeer  
University of Melbourne
A Precision Medicine program in Mesothelioma (2022 - 2024) 
This project is funded through the generous support of the Lyall Watts Mesothelioma Research Fund. 

Prof Ricky Johnstone, Dr Stephin Vervoort 
University of Melbourne
New therapies for Multiple Myeloma (2022 - 2024)

Prof Laura Mackay
University of Melbourne
Targeting local immune cells to improve cancer treatments (2022 - 2024) 

Prof Stephen Nutt, Dr Julie Tellier 
Walter and Eliza Hall Institute of Medical Research
Targeting plasma cells to treat liver cancer (2022 - 2024) 

Prof Joseph Trapani, Dr Laura Porter 
University of Melbourne
Using anti-cancer drugs to stimulate an immune response to cancer (2022 - 2024)

Projects commenced in 2021

Dr Rishu Agarwal,  Dr Philip Thompson, Prof Constantine Tam, Prof Sarah-Jane Dawson, Prof Mark Dawson
Peter MacCallum Cancer Centre
Circulating tumour DNA and genomic markers of poor response to Ibrutinib-Venetoclax combination therapy in chronic lymphocytic leukaemia (2021 -2023)

A/Prof Ian Campbell,  A/Prof Paul James, Dr Na Li
Peter MacCallum Cancer Centre
Finding new genes that cause familial high grade serious ovarian cancer (2021 -2023)

A/Prof Prudence Francis, Prof Sherene Loi, Prof Sarah Jane Dawson
Peter MacCallum Cancer Centre
Understanding response to neoadjuvant therapy in hormone receptor positive breast cancer; a correlative analysis of the ELIMINATE trial (2021 -2023) 

A/Prof Marco Herold,  Prof Tony Papenfuss
Walter and Eliza Hall Institute of Medical Research
Looking beyond the role of mutant DNMT3a in AML (2021- 2023)

Prof Brendan Jenkins,  Dr Daniel Croagh, A/Prof Marina Pajic, Prof Yana Zavros
Hudson Institute of Medical Research
Uncovering the broad clinical utility of the innate immune pattern recognition receptor, Toll-like receptor 2, in pancreatic cancer (2021 -2023) 

Dr Linh Nguyen, Prof John Hopper, Dr Gillian Dite, Dr Shuai Li, Prof Pam Bell, Mrs Gerda Evans, Prof Joohon Sung
University of Melbourne
Combining novel breast cancer risk factors to produce automated and accurate personalised breast cancer risk prediction at the time of mammographic screening (2021 -2023) 

Prof Anthony Purcell, Prof Bruce Robinson
Monash University
Defining the antigenic landscape of malignant mesothelioma - new opportunities for immunotherapy (2021 -2023) 
This project is funded through the generous support of the Lyall Watts Mesothelioma Research Fund. 

A/Prof Erica Sloan,  Dr Fiona Hegi-Johnson, Prof Robin Anderson, Prof Michael MacManus, Prof Scott Mueller
Monash University
Harnessing neural-immune communication to enhance the radiotherapy abscopal response (2021 -2023) 

A/Prof Jeanne Tie,  Prof Peter Gibbs, A/Prof Sue-Anne McLachlan, Dr Craig Underhill, Prof Niall Tebbutt, Prof Alexander Heriot, Dr Julie Chu, Prof Michael Jefford, Dr Tim Akhurst
Walter and Eliza Hall Institute of Medical Research
RESOLUTE: Randomised phase II trial to evaluate the strategy of integrating local ablative therapy with first-line systemic treatment for unresectable oligometastatic Colorectal cancer (2021 -2023) 

Dr Daniel Utzschneider,  Prof Stephen Opat, Prof Constantine Tam, Prof Axel Kallies
Peter Doherty Institute, University of Melbourne
Characterization and targeting of T cells for the treatment of leukemia (2021 -2023) 

Dr Ajithkumar Vasanthakumar,  Dr Bhupinder Pal, Dr Simon Tsao, Prof Axel Kallies
Peter Doherty Institute, University of Melbourne
Targeting regulatory T cells in mammary adipose tissue to treat breast cancer (2021 -2023) 

A/Prof Ilia Voskoboinik,  Prof Joseph Trapani, Prof Constantine Tam
Peter MacCallum Cancer Centre
How to overcome tumour resistance to immunotherapy (2021 -2023) 

Prof Ingrid Winship,  Dr Khalid Mahmood, A/Prof Daniel Buchanan, Mr Peter Georgeson, Ms Emma Barrance, Ms Natalie Diepenhorst, Ms Julie Toner
University of Melbourne
What can tumour mutational signatures tell us about the cause of familial colorectal cancer? (2021 -2023)

Projects commenced in 2020

Dr Holly Barker, Dr Kristy Shield-Artin, Dr Cassandra Vandenberg and Dr Gayanie Ratnayake 
The Walter and Eliza Hall Institute of Medical Research
Identifying new treatment options for the rare and aggressive ovarian carcinosarcoma (2020 -2022)
Co-funded by the Ovarian Cancer Research Foundation 

Dr Paul Beavis, Prof Phillip Darcy, Prof Benjamin Solomon and Prof Sherene Loi
Peter MacCallum Cancer Centre
Enhancing cell-based therapy of cancer (2020 -2022)

A/Prof Daniel Buchanan, Prof Mark Jenkins, Prof Ingrid Winship, Prof Finlay Macrae, Prof Alex Boussioutas and A/Prof Christophe Rosty
University of Melbourne
Why does colonoscopy fail to prevent cancer of the large bowel in people with Lynch syndrome? (2020 -2022)

Prof Suzanne Cory and Dr Gemma Kelly
The Walter and Eliza Hall institute of Medical Research
Testing a promising new therapeutic target (MNT) to improve treatment of diverse human lymphomas and other cancers driven by high levels of the oncoprotein MYC (2020 -2022)

Prof Paul Donnelly and A/Prof Carleen Cullinane
University of Melbourne
Diagnostic imaging and therapy of cancers with copper radiopharmaceuticals (2020 -2022)

Dr Debra Gook, A/Prof David Westerman and Prof Claus Anderson
The Royal Women’s Hospital
Eliminating leukemic cells from ovarian tissue for safe restoration of fertility (2020 - 2022)

Dr Ian Majewski and Dr Peter Valk
The Walter and Eliza Hall Institute of Medical Research
How does the DNA damage that accumulates with age influence cancer risk? (2020 -2022)

Dr Delphine Merino, Dr Melissa Davis and Dr Belinda Yeo
Olivia Newton-John Cancer Research Institute
Design new treatments for patients with aggressive breast cancer using sequencing and drug response prediction (2020 -2022)

Dr Ashley Ng, Dr Kira Behrens, Prof Warren Alexander,  Dr Rebecca Feltham, Prof John Silke and Dr David Komander
The Walter and Eliza Hall Institute of Medical Research
Drugging Undruggable Targets in Ph+ B-cell Acute Lymphoblastic Leukaemia (2020 -2022)

Prof Richard Pearson
University of Melbourne
Combinatorial targeting of cellular “housekeeping” processes to treat cancer (2020 -2022)

Prof Andrew Perkins
Monash University
Towards a cure for myelofibrosis  (2020 -2022)
Funded by the Victorian Government through the Victorian Cancer Agency 

A/Prof Jake Shortt and Dr Lev Kats
Monash University
Determining the reasons why leukaemia and lymphoma become resistant to treatments that alter
the methylation of cancer DNA (2020 -2022)

Dr Lorey Smith and Dr Brendon Monahan
Peter MacCallum Cancer Centre
Preventing Resistance to Targeted Therapy in Melanoma (2020 -2022)

Dr Florian Wiede
Peter MacCallum Cancer Centre
Enhancing the immune system in combating liver cancer in obesity (2020 -2022)
Funded by the Victorian Government through the Victorian Cancer Agency 

Projects commenced in 2019

Prof Robin Anderson, Prof Robert Parton
Olivia Newton-John Cancer Research Institute


Dr Nicholas Clemons, Prof Wayne Phillips, Dr Gang Chen, Dr Cuong Duong, A/Prof Sarah-Jane Dawson, Prof David Watson, Prof Reginald Lord, A/Prof David Wang
The University of Melbourne
Development of a simple blood test to guide treatment decisions for patients with oesophageal cancer (2019-2021)
Funded by the Victorian Government through the Victorian Cancer Agency 
Dr James Dowty, A/Prof Daniel Buchanan, Prof Ingrid Winship, A/Prof Robert Waterland, Dr Jihoon Joo, Prof Mark Jenkins, Prof Melissa Southey
The University of Melbourne


Dr Moritz Eissmann, Prof Matthias Ernst, Prof Alex Boussioutas
La Trobe University
Testing antibodies inhibiting IL33-signalling against gastric cancer (2019-2021)
Funded by the Victorian Government through the Victorian Cancer Agency 


A/Prof Thomas Gebhardt
The University of Melbourne
Dr Catherine Granger
The University of Melbourne
A randomised control trial to evaluate the effect of exercise and self-management on outcomes of people with operable lung cancer (2019-2021)
Funded by the Victorian Government through the Victorian Cancer Agency 
Dr Lev Kats, Prof Ricky Johnstone
Peter MacCallum Cancer Centre
Dr Simon Keam
Peter MacCallum Cancer Centre
Prof John Mariadason
Olivia Newton-John Cancer Research Institute
Prof Neil O'Brien-Simpson, A/Prof Andrea O'Connor, Prof Michael McCullough, Dr Jason Lenzo
The University of Melbourne
Dr Lorraine O'Reilly, Prof Andreas Strasser, A/Prof Nicholas Huntington
The Walter and Eliza Hall Institute of Medical Research
A/Prof Louise Purton, A/Prof Carl Walkley, Dr Meaghan Wall, Dr Helene Jousset
St Vincent's Institute of Medical Research
Prof Andrew Scott, A/Prof Hui Gan, Prof Weisan Chen
Olivia Newton-John Cancer Research Institute
Prof Matthew J. Watt, Dr Renea A. Taylor, A/Prof Daniel Nomura
The University of Melbourne

Projects commenced in 2018

Dr Ashwini Chand, Prof Matthias Ernst, Prof Michael Parker
La Trobe University
Repurposing drugs for the treatment of gastrointestinal cancers (2018-2020)


A/Prof Phillip Darcy, Dr Paul Beavis, Prof Dale Godfrey
Peter MacCallum Cancer Centre
Investigating the role of a novel immune cell subset in cancer (2018-2020)


Dr Daniel Gough, Prof David Watkins, Dr Kate Sutherland, A/Prof Jake Shortt
Hudson Institute of Medical Research
Identifying new treatments for platinum resistant Small Cell Lung Cancer (2018-2020) 


A/Prof Daniel Gray, Prof David Huang, Prof Andrew Roberts, Prof Terence Speed
The Walter and Eliza Hall Institute of Medical Research
Understanding how new therapies target blood cancer (2018-2020)


A/Prof Craig Harrison, Dr Paul Gregorevic, A/Prof Jose Garcia
Monash University
Towards precision medicine for cancer cachexia (2018-2020)


A/Prof Christine Hawkins, Prof Andrew Scott, A/Prof Carl Walkley
La Trobe University
Testing new drugs for bone cancer (2018-2020)


A/Prof Thomas John, Prof Andrew Scott, A/Prof Hui Gan
The Olivia Newton-John Cancer Research Institute
New treatments for mesothelioma (2018-2020)


Prof Ricky Johnstone, A/Prof Jake Shortt
Peter MacCallum Cancer Centre
Targeting transcriptional addiction for cancer therapy (2018-2020)


Dr Gemma Kelly, Dr Marco Herold, Dr MaryAnn Anderson
The Walter and Eliza Hall Institute of Medical Research
Investigating a novel anti-cancer agent targeting MCL-1 for the treatment of haematological cancers (2018-2020)


Prof Christina Mitchell, Prof Catriona McLean
Monash University
Regulation of phosphoinositide 3-phosphate tumour suppressor activity (2018-2020)


Dr Donia Moujalled
Monash University
New treatments for Acute lymphoblastic leukaemia (2018-2020)


Prof David Ritchie, Dr Nicholas Huntington
The University of Melbourne
Inhibiting immune cell function to improve stem cell transplant outcomes in leukaemia (2018-2020)


Prof Tony Tiganis, Prof Catriona McLean
Monash University
Determining how liver cancer develops in obesity (2018-2020)


Projects commenced in 2017

Dr Urmi Dhagat, Dr Sophie Broughton, Prof Michael Parker, A/Prof Louise Purton
The University of Melbourne (2018-2019); St Vincent's Institute of Medical Research (2017-2018)
How does the protein hormone interleukin-3 regulate cell signalling in leukaemic cells? (2017-2019) 


A/Prof Hui Gan, Prof Andrew Scott, Prof John Mariadason, A/Prof Elgene Lim, Prof Niall Tebbutt
La Trobe University
Anti-EGFR drug conjugates for the treatment of colorectal and breast cancer  (2017-2019) 


Prof Suzanne Garland, Prof Sepehr Tabrizi, A/Prof Richard Hillman, Dr Alyssa Cornall, Dr Fengyi Jin, Dr Jennifer Roberts, Dr Isobel Poynten, Dr Monica Molano, Dr Dorothy Machalek
The University of Melbourne
Assessment of potential tests for anal cancer screening (2017-2019)


Prof John Hopper, Dr Daniel Schmidt, Dr Enes Makalic, Dr Carmel Apicella, Dr Louise Keogh, Dr Helen Frazer, Dr Pierre-Antoine Dugue, Dr Ralph Highnam, Mr Kevin Nguyen, Dr Jill Evans
The University of Melbourne
Automated measures that predict risk and masking of breast cancer  (2017-2019)


Dr Peter Janes, Prof Andrew Scott, A/Prof Thomas John
Monash University (2017-2018); La Trobe University (2018-2019)
Targeted antibody therapy for malignant mesothelioma 
Lyall Watts Mesothelioma Research Grant (2017-2019)


Dr Ian Majewski, Prof David Huang, Prof Andrew Roberts
The Walter and Eliza Hall Institute of Medical Research
Targeting cell survival pathways to treat cancer (2017-2019) 


Dr Kate Murphy, Prof John Silke, Prof Gordon Lynch, Prof Leanne Delbridge
The University of Melbourne
A novel treatment for heart failure in cancer and with chemotherapy (2017-2019)


Dr Lan Nguyen
Monash University
Elucidating the dual functions of YAP in breast cancer (2017-2019) 


Dr Belinda Parker, A/Prof Phil Darcy
La Trobe University
Predicting the benefit of therapies for patients with triple negative breast cancer (2017-2019)


A/Prof Helena Richardson, A/Prof Patrick Humbert, Prof Josef Penninger
La Trobe University
Determining how a novel protein controls cell shape and cancer progression  (2017-2019)


Dr Adam Uldrich, Dr Daniel Pellicci, Dr Ilia Voskoboinik
The University of Melbourne
Examining the anti-cancer properties of gamma delta T cells (2017-2019) 
A/Prof Carl Walkley, A/Prof Wallace Langdon, Dr Meaghan Wall, Dr Alistair Chalk
St Vincent's Institute of Medical Research
Understanding how blood cancers form (2017-2019) 

Projects commenced in 2016

A/Prof Kieran Harvey, Dr Nicola Waddell, A/Prof Kaylene Simpson
Peter MacCallum Cancer Centre
What causes mesothelioma and how can we treat it?
Lyall Watts Mesothelioma Research Grant (Sept 2016 - Aug 2019)


Dr Nicole Haynes, Prof Ricky Johnstone, A/Prof Sherene Loi
The University of Melbourne (Peter MacCallum Cancer Centre)
Targeting HER2+ breast cancer with novel combination therapies (2016-2018)


Dr Peter Janes, Prof Dimitar Nikolov, Dr Elgene Lim
Monash University
Novel therapeutic antibodies to fight drug resistant breast cancers  (2016-2018)


Prof Stephen Nutt, A/Prof Lynn Corcoran
The Walter and Eliza Hall Institute of Medical Research
Exploring new molecular targets on plasma cells as therapies for multiple myeloma  (2016-2018)


Dr Gretchen Poortinga, Prof Grant McArthur, Prof Ross Hannan
Peter MacCallum Cancer Centre
Understanding how cancer cells become resistant to a novel treatment of blood cancers (2016-2018) 


A/Prof Louise Purton, Dr Meaghan Wall, Dr Carl Walkley
St Vincent's Institute of Medical Research
Identifying better treatments for blood cell cancers (2016-2018)


Prof Jamie Rossjohn, Prof Andrew Brooks
Monash University
Exploring how tumour cells are recognised by Natural Killer cells (2016-2018)


Dr Karen Sheppard, Prof Grant McArthur
Peter MacCallum Cancer Centre
Understanding why melanomas stop responding to therapy that inhibits cells from growing  (2016-2018)


Prof Andreas Strasser, Dr Daniel Gray
The Walter and Eliza Hall Institute of Medical Research
How does competition between cells impact tumour development (2016-2018)


Prof Jose Villadangos, Prof William Heath
The University of Melbourne
Improving cancer killing with live cell therapy (2016-2018)


Dr Florian Wiede
Monash University (2016-2017); The University of Melbourne (2018)
Defining a novel immunotherapy for more effective cancer treatment (2016-2018)